Safety of thymopentin. Data from European clinical studies.
The safety data collected from 196 patients treated with thymopentin during the clinical development of this compound in Europe are reviewed and compared with the incidence of adverse drug reactions experienced when using a commercial nonsteroid anti-inflammatory drug. Quantitatively side effects are reported in the same range for both drugs, however, they appear to be quite different when classified by body systems. Some patients complained about somnolence, and it is speculated whether this symptom might be related to thymopentin's known effect on the neuromuscular junction. The general conclusion is that thymopentin is an extremely well tolerated drug when used according to the dose regimens recommended.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D006801:Humans; D010446:Peptide Fragments / Q000009:adverse effects*; D011817:Rabbits; D012449:Safety; D012867:Skin / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000139:chemically induced; D016305:Thymopentin; D013946:Thymopoietins / Q000009:adverse effects*; D013951:Thymus Hormones / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin